Format

Send to

Choose Destination
Cancer Cell. 2011 Mar 8;19(3):347-58. doi: 10.1016/j.ccr.2011.01.040.

Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.

Author information

1
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.

Abstract

We screened 124 genes that are amplified in human hepatocellular carcinoma (HCC) using a mouse hepatoblast model and identified 18 tumor-promoting genes, including CCND1 and its neighbor on 11q13.3, FGF19. Although it is widely assumed that CCND1 is the main driving oncogene of this common amplicon (15% frequency in HCC), both forward-transformation assays and RNAi-mediated inhibition in human HCC cells established that FGF19 is an equally important driver gene in HCC. Furthermore, clonal growth and tumorigenicity of HCC cells harboring the 11q13.3 amplicon were selectively inhibited by RNAi-mediated knockdown of CCND1 or FGF19, as well as by an anti-FGF19 antibody. These results show that 11q13.3 amplification could be an effective biomarker for patients most likely to respond to anti-FGF19 therapy.

PMID:
21397858
PMCID:
PMC3061399
DOI:
10.1016/j.ccr.2011.01.040
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center